Hologic plans to buy Reveal Genomics. What does HER2DX add?
The deal is not closed. A 27-gene tissue test and OpenOnco's public rules answer different questions; changed decisions are not proof of better outcomes.
Written retrospectively and published on October 20, 2026.
A company announcement is not independent evidence of clinical benefit. This comparison is informational, not medical advice. This article does not replace a doctor.
On 19 October, Hologic said it signed an agreement to acquire Barcelona startup Reveal Genomics. The deal still needs Spanish regulatory approval and other closing conditions. Reveal's HER2DX measures expression of 27 genes in preserved breast-tumor tissue and combines it with stage and nodal status to report relapse risk, likelihood of a pathological complete response and ERBB2 expression. Reveal says the US test runs in a CLIA-certified, CAP-accredited laboratory; European CE marking is still underway. Its product page asks clinicians to contact the company to order and publishes no price or source-code licence.
In a prospective observational study at 12 Spanish hospitals, clinicians reported treatment adjustments after HER2DX in 48.1% of 297 cases. The study had no randomized comparison or evidence that those changes improved survival; several authors had company roles or interests. OpenOnco instead offers free browser-based review of source-linked oncology rules under an MIT code licence. Anyone can inspect those rules, but OpenOnco cannot analyze tumor tissue or produce a HER2DX score. A genomic test cannot replace checking guidelines either. There is no head-to-head outcomes comparison. Sources and comparison checked 20 October 2026. This article does not replace a qualified physician.
Comments
Threads are public and indexed — please keep personal medical data out of them. Found a clinical error? Open an issue instead.
Comments are not switched on yet — the backend still needs to be configured.